Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | AZUR-1: dostarlimab as a new standard-of-care in dMMR/MSI-H LARC?

David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the findings from the single-arm AZUR-1 (NCT05723562) trial evaluating anti-PD-1 dostarlimab in patients with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer (LARC), with a primary endpoint of clinical complete response maintained at least for 12 months. The results show a 26% complete response rate, which increases to 76% when including patients with surgical and pathological complete response. Dr Tougeron emphasizes the potential for immunotherapy and non-operative management to become a new standard of care for MSI patients, avoiding the need for chemotherapy, radiation, and surgery. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.